Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 200 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR FDA Approves Sacituzumab Govitecan-hziy for HR-positive Advanced Breast Cancer February 15, 2023 Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45... January 15, 2022 Hormone Therapy for Prostate Cancer? A Genetic Test Could Help Decide March 15, 2021 Ibrutinib-Containing Immunochemotherapy in Front-Line Treatment of Young, Medically Fit Patients with... May 14, 2024 Load more HOT NEWS A Novel Combination of Cabozantinib Plus Atezolizumab Demonstrates Encouraging Activity and... Child Cancer Patient And His Dad Have A Little Fun When... Patient Guide in Bladder Cancer Now Available Also in Italian 105-Year-Old Woman Sets Record For 100-Meter Dash
